Company Behind a Revolutionary Treatment That May Grow New Heart Tissue Expands On Its Business Model On Bio Business Networks.Business Editors/Health & Medical Writers HOUSTON--(BUSINESS WIRE)--July 26, 2002 Dr. David P. Summers, Chief Executive Officer of Endovasc Ltd (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :ENVC), is featured on BioBusiness Networks - a media organization focusing on providing information for investors in healthcare and biotechnologies industries. Other featured companies include Praecis Pharmaceuticals (Nasdaq:PRCM PRCM Power, Reset and Clock Management PRCM Master Chief Parachute Rigger (Naval Rating) PRCM Passive Radiation Countermeasures PRCM Parallel Relay Channel Model ) and Cyanotech (Nasdaq:CYAN). The 15-minute audio interview of Dr. Summers is accessible at www.BioBN.com. In the interview, Summers discusses current business conditions and the company's strategic outlook. Endovasc focuses on the development of drugs for the vast cardiovascular and metabolic markets, accounting for more than USD USD In currencies, this is the abbreviation for the U.S. Dollar. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. 69 billion in sales volume per year -- 25% of the entire pharmaceutical market. Its flagship treatment -- approved for Phase III FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. human clinical trials -- is ANGIOGENIX(TM), a revolutionary way to stimulate the robust growth of new blood vessels in the patient's heart. Trials at Columbia University demonstrated that -- using Endovasc's treatment, 80% of test animals with an artificially-induced heart failure grew new blood vessels and heart tissue to replace the damaged part of their hearts, regaining heart function. The Company said Stanford researchers found stem cell replacement tissues in previous animal models of ischemia and the restoration of cardiac function found in the heart-failure model at Columbia may be more than angiogenesis -- it might be a combination of new blood vessel growth and endogenous stem cells making new heart muscle cells. This re-growth of the heart tissue and restoration of cardiac function would explain a process called Cardiogenesis ... the actual renewal of the heart. About BioBusiness Networks BioBusiness Networks, www.BioBN.com, is an interactive investor & medical education company. The firm's analysts provide comprehensive market data and breaking financial news. BioBusiness Review Inc. is the online and offline investment and business journal covering the Healthcare industry. The company's original and aggregated content is available on multiple channels including the Internet, voice portals, wireless devices, and high-speed broadband networks. Biobn.com programming is available to millions of users through its partnerships. About Endovasc Endovasc is a biotechnology company that focuses on curing debilitating de·bil·i·tat·ing adj. Causing a loss of strength or energy. Debilitating Weakening, or reducing the strength of. Mentioned in: Stress Reduction cardiovascular diseases resulting from arteriosclerosis arteriosclerosis (ärtĭr'ēōsklərō`sis), general term for a condition characterized by thickening, hardening, and loss of elasticity of the walls of the blood vessels. (hardening of the arteries hardening of the arteries: see arteriosclerosis. ), diabetes, neurovascular and neurodegenerative disease, and congestive heart failure congestive heart failure, inability of the heart to expel sufficient blood to keep pace with the metabolic demands of the body. In the healthy individual the heart can tolerate large increases of workload for a considerable length of time. (CHF CHF In currencies, this is the abbreviation for the Swiss Franc. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. ). The company has developed proprietary pioneering drugs and delivery technologies that deliver and release drugs to their intended targets by: (1) encapsulating drugs in "germ-sized" microspheres called liposomes Liposomes Aqueous compartments enclosed by lipid bilayer membranes; liposomes are also known as lipid vesicles. Phospholipid molecules consist of an elongated nonpolar (hydrophobic) structure with a polar (hydrophilic) structure at one end. , which can target a single cell, and (2) small artificial metal and polymer scaffolds called vascular stents, which when placed in a blood vessel can restore the function of the artery to supply blood to blood-starved areas such as the area damaged by a heart attack. Cardiovascular and diabetes markets account for more than USD 69 billion in sales volume per year -- 25% of the entire pharmaceutical market. Cardiovascular diseases are the number one cause of death in the western world today. They account for 50% of deaths worldwide, nearly double of those caused by cancer, the second most prevalent cause of death. Diabetes is the fastest growing disease in the United States. It is estimated that in the U.S. alone, the economic cost of these diseases is over USD 250 billion per year. To sign up for Endovasc shareholder alerts, please visit http://www.endovasc.com/html/e-list.html The foregoing statements are made under the "Safe Harbor" Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 and may contain forward-looking statements that involve risks and uncertainties that may not be evident at the time of this release. For more information about Endovasc, please visit www.endovasc.com. Please read the Company's filings with the Securities and Exchange Commission -- see www.freeedgar.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion